The DOI matches its Crossref record.
The Liver Meeting: Boston, Massachusetts Nov 10-14, 2023
Abstract
Background: There is a lack of knowledge on the burden of invasive fungal disease in patients with severe alcoholic hepatitis. Methods: Among the 1,438,049 patients diagnosed with alcohol use disorders in French hospitals between 2012 and 2021, we selected individual’s with hepatic failure, portal hypertension bleeding, transjugular liver biopsy, or extrahepatic organ failure within 4 weeks following the diagnosis of alcoholic hepatitis. Our primary objective was to investigate the incidence of invasive fungal disease abd to assess the associated risk factors. We examined the 6-month mortality rate as an outcome measure. The main exposure was invasive fungal disease, while bacterial pneumonia served as the control exposure. To assess the strength of the associations, we employed multivariate logistic regression models and Cox proportional hazards models stratified by age categories, severe comorbidities, and deprivation. Results: The sample comprised 30,361 patients. Median (interquartile range) age was 55.0 (47.0-62.0) years and 73% were men. Invasive fungal disease [invasive candidosis (n=269, 0.9%); aspergillosis (n=105, 0.3%); pneumocystosis (n=47, 0.2%); cryptococcosis (n=3, 0.01%)] and bacterial pneumonia were diagnosed in 411 (1.4%) and 8,787 (10.8%) of patients, respectively. Approximately one-fifth (19.7%) of patients were documented with sepsis, and one-fourth progressed to extrahepatic organ failure. The 6-month mortality rate was ~1/4 (26.5%). Multivariate associations comprised younger ages [aOR 0.73 per decade, 95% CI (0.66-0.81) P<0.001]; sepsis [aOR 3.32, (2.63-4.21) P<0.001]; bacterial pneumonia [aOR 3.09 (2.48-3.85) P<0.001]; extrahepatic organ failure [aOR 2.19 (1.72-2.80) P<0.001]; severe comorbidities [aOR 1.14 (1.00-1.30) P<0.001]; and 6-month mortality [aOR 2.98 (2.40-3.71) P<0.001]. The probabilities of 6-month survival (95% CI) were 72.2 (71.7-72.7) and 40.5 (35.9-45.9) percent without and with invasive fungal disease, respectively (P<0.001), and 73.3 (72.8-73.9) and 63.2 (61.7-64.6) percent without and with bacterial pneumonia, respectively (P<0.001). Invasive fungal disease was associated with an independent, increased, instant, risk of 6-month death of ~80% [aHR 1.81 95% CI (1.58-2.08), P<0.001]. Bacterial pneumonia was not associated with mortality. Conclusion: Invasive fungal disease, and not bacterial pneumonia, increased the risk of 6-month mortality in patients with severe alcoholic hepatitis in France 2012-2021.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, weight loss-mediated improvement of MASLD-related steatosis did not necessarily depend on normalization of glycemia in RCTs with caloric restriction or sodium-glucose co-transporter 2 inhibitor (SGLT2I) treatment [97][98][99].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [99]
In the citing paper
“The dual α/δ PPAR agonist elafibranor failed to prove superiority to placebo in a 72-week phase 3 study regarding the primary endpoint MASH resolution without worsening of fibrosis (19 vs 15 % resolution rate) and also for fibrosis improvement (25 vs 22 %) [184].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [184]
Citations
Cited by
Sorted by citations
Linge, J., Birkenfeld, A. L., & Neeland, I. J. (2024) · Circulation · doi:10.1161/circulationaha.124.067676 · Cited by 180
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169
Metadata
- Authors
- Cadamuro, M., Haxhiaj, L., Montanaro, C., Villa, E., Floreani, A., Cazzagon, N., Baggio, G., Strazzabosco, M., Simioni, P., & Fabris, L.
- Affiliations
- Université Paris Cité (FR)
- Hôpital Cochin (FR)
- Inserm (FR)
- Hôpital Saint-Louis (FR)
- Venue
- Hepatology
- Published
- 2023-10
- Volume
- 78
- Issue
- S1
- Pages
- S1-S2154
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W4387517212
- Cited by
- 32
- References
- 0
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 24
- FWCI
- 6.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Funders
- National Institute for Health and Care Research (ACF-2022-13-004)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- liver disease
- MeSH terms
- Boston, Liver, Massachusetts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review